A Kampo formulation: Byakko-ka-ninjin-to (Bai-Hu-Jia-Ren-Sheng-Tang) inhibits IgE-mediated triphasic skin reaction in mice: the role of its constituents in expression of the efficacy.
We have demonstrated that oral administration of a Kampo formulation, Byakko-ka-ninjin-to (Bai-Hu-Jia-Ren-Sheng-Tang), inhibited IgE-mediated triphasic skin reaction, including immediate phase response (IPR), late phase response (LPR) and very late phase response (vLPR), in passively sensitized mice with anti-DNP IgE antibody. Variant formulations of Byakko-ka-ninjin-to without Gypsum Fibrosum (Sekko), Glycyrrhizae Radix (Kanzo) or Oryzae Semen (Kobei) attenuated the inhibitory effect as compared with that of Byakko-ka-ninjin-to. The decreased effect of Byakko-ka-ninjin-to without Kanzo was restored by the addition of Kanzo to the variant formulations before oral administration, while the decreased effect of Byakko-ka-ninjin-to without Sekko could not be recovered by the addition of Sekko. Comparison of HPLC profiles of variant formulations without one crude drug with that of original Byakko-ka-ninjin-to revealed that some peaks could be detected only when five constituent crude drugs were simultaneously present during the preparation of Byakko-ka-ninjin-to formulation. Since elimination of Sekko from the Byakko-ka-ninjin-to constituents attenuated the efficacy although it did not show any activity per se, mutual interaction of Sekko with other constituents during the preparation may result in the production of new components. These findings suggest that the effect of Byakko-ka-ninjin-to formulation on cutaneous inflammatory disease can differ from the sum of the effect of the individual constituents.
Department of Pathogenic Biochemistry, Institute of Natural Medicine, Department of Japanese Oriental (Kampo) Medicine, Faculty of Medicine, Toyama Medical and Pharmaceutical University, Sugitani.
T
T
Tatsumi
T
T
Yamada
H
H
Nagai
K
K
Terasawa
T
T
Tani
S
S
Nunome
I
I
Saiki
D019297:2,4-Dinitrophenol / Q000494:pharmacology; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D003877:Dermatitis, Contact / Q000188:drug therapy* / Q000276:immunology; D004365:Drugs, Chinese Herbal; D004431:Ear, External / Q000473:pathology; D007073:Immunoglobulin E / Q000276:immunology*; D008297:Male; D020835:Medicine, Kampo; D051379:Mice; D008807:Mice, Inbred BALB C; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D011241:Prednisone / Q000494:pharmacology; D012503:Saponins / Q000737:chemistry / Q000494:pharmacology*; D013056:Spectrophotometry, Ultraviolet; D013997:Time Factors; D014475:Uncoupling Agents / Q000494:pharmacology
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D004365:Drugs, Chinese Herbal; D012503:Saponins; D014475:Uncoupling Agents; C108060:byakko-ka-ninjin-to; D007073:Immunoglobulin E; D019297:2,4-Dinitrophenol; D011241:Prednisone